Puri, Sonam

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC

Le, X., Puri, S., Negrao, M. V., Nilsson, M. B., Robichaux, J., Boyle, T., Hicks, J. K., Lovinger, K. L., Roarty, E., Rinsurongkawong, W., et al. (2018) · Clinical Cancer Research

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 387

Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial

Kuboki, Y., Fakih, M., Strickler, J., Yaeger, R., Masuishi, T., Kim, E. J., Bestvina, C. M., Kopetz, S., Falchook, G. S., Langer, C., et al. (2024) · Nature Medicine

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 103

Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study.

Neal, J. W., Santoro, A., Viteri, S., Ponce Aix, S., Fang, B., Lim, F. L., Gentzler, R. D., Goldschmidt, J. H., Khrizman, P., Massarelli, E., et al. (2022) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 18

MA 12.05 Genomic Profiling of EGFR T790M Mutated Non-Small Cell Lung Cancer to Evaluate the Mechanisms of Resistance to Osimertinib

Puri, S., Hicks, J., Knepper, T., Smith, M., Boyle, T., & Gray, J. (2017) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 10